Key terms
About ALXO
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALXO news
Mar 11
6:07am ET
ALX Oncology price target raised to $20 from $17.50 at H.C. Wainwright
Mar 08
9:45am ET
ALX Oncology’s Evorpacept Shows Promising Potential in Cancer Treatment Studies
Mar 08
8:00am ET
ALX Oncology price target raised to $21 from $11 at Piper Sandler
Mar 08
7:50am ET
Analysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)
Mar 07
9:51pm ET
ALX Oncology downgraded to Hold from Buy at Stifel
Mar 07
4:06pm ET
ALX Oncology reports Q4 EPS (93c), consensus (84c)
Feb 09
12:40am ET
Analysts Are Bullish on Top Healthcare Stocks: Haemonetics (HAE), ALX Oncology Holdings (ALXO)
Dec 14
10:50am ET
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
Dec 14
5:55am ET
Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call
No recent news articles are available for ALXO
No recent press releases are available for ALXO
ALXO Financials
Key terms
Ad Feedback
ALXO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALXO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range